As of Wednesday, January 07, Olema Pharmaceuticals, Inc.’s OLMA share price has surged by 6.59%, which has investors questioning if this is right time to sell.
Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said ...
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global ...
A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may ...
“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...
Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.
Long COVID—defined as symptoms persisting ≥ 2 months beyond acute SARS-CoV-2 infection without alternative explanation—now ...
Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, regulatory filings, and potential M&A.
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As compared with fulvestrant alone, the combination more than doubled the median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback